• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to navigation
Close Ad

The Spoon

Daily news and analysis about the food tech revolution

  • Home
  • Podcasts
  • Events
  • Newsletter
  • Connect
    • Custom Events
    • Slack
    • RSS
    • Send us a Tip
  • Advertise
  • Consulting
  • About
The Spoon
  • Home
  • Podcasts
  • Newsletter
  • Events
  • Advertise
  • About

SuperGut

January 31, 2024

Food as Medicine Platform Foodsmart Expands Reach to 7.4 Million Patients as it Reels in $10M in Fresh Funding

Today, food as medicine and telehealth startup Foodsmart announced an expansion of its “Foodscripts” program and a new round of funding. The company says it will reach up to 7.4 million patients across three major healthcare systems: Advocate Health, Memorial Hermann Health System, Intermountain Health. These healthcare systems, alongside the American College of Cardiology and Glen Tullman’s 62 Ventures, have invested $10 million as part of an expanded Series C investment (now up to $40M) as part of the expansion.

The company is part of the food-as-medicine movement, which encourages healthier eating to create a healthier life overall.  As chronic diseases continue to be a predominant health issue in the United States, there have been calls for our health system to provide better nutritional guidance to patients. The growth in food-as-medicine has come alongside growing usage by at-risk patients of GLP-1 drugs as a reasonably fast way to manage their weight. However, GLP-1 drugs are expensive and often require daily self-administered injections. Foodsmart and other food-as-medicine proponents see “food care” as a better, longer-term, and less costly solution, as well as one that can be paired with initial “jump starter” usage of GLP-1 drugs to get quicker and sustained outcomes.

In an email to The Spoon, Foodsmart outlined the different components of the program expansion:

  1. Extended Reach: The program will be extended to 7.4 million patients across the funding healthcare systems, which the company says represents a substantial increase in its impact and potential to improve health outcomes.
  2. Enhanced Funding: The additional $10 million funding brings the total Series C investment to $40 million.
  3. Strategic Partnerships: Collaborations with healthcare systems and organizations, which Foodsmart says emphasize the importance of integrating nutrition into healthcare and highlight Foodscripts’ potential to transform patient care.
  4. EHR Integration: Foodsmart has developed an Electronic Health Record (EHR) integration, which they say will enable providers to enter and track Foodscripts more easily for insurance purposes.
  5. Upskilling Providers: Foodsmart will start emphasizing upskilling healthcare providers. This involves educating them on the latest scientific data and best practices for addressing the nutritional needs of patients with various chronic diseases.

The growth in offerings within the formalized healthcare community around nutrition guidance comes at a time of increased attention among technology platform providers around personalized nutrition and metabolic health management. Startups like January.AI are providing AI-powered solutions that help those at risk of metabolic disease ways to manage their caloric intake and the impact on their blood glucose levels without having to use a continuous glucose monitor. Other startups like Supergut are tapping into the growing awareness of metabolic health – largely driven by rising awareness of the impact of GLP-1 drugs – by providing over-the-counter supplement approaches that claim to have some of the same benefits as these medications.

Investment in this space has been a countervailing trend to slowing interest among venture investors in plant-based food and other better-for-you offerings, which has been victimized in part by a broader venture slowdown as well as slower-than-expected growth of some of the high-profile, high-fliers in the space, such as Beyond Meat and Impossible Foods.

November 17, 2023

Podcast: Why Are CPG Brands Freaking Out About Ozempic?

On this week’s Spoon Podcast, SuperGut CEO Marc Washington joins me to talk about why new GLP-1 drugs like Ozempic and Wegovy keep CPG brand CEOs up at night.

These new drugs, which got their start as a new class of pharmaceuticals that help control type 2 diabetes, have become very popular in recent years as weight loss miracle drug. They are hugely effective in suppressing appetites and reducing the overall calorie intake of those taking them, so much so that some speculate that they could have a significant impact on the overall demand for food if, as predicted, tens of millions begin to take them in coming years as prices come down and they become available in more accessible formats. 

Marc’s company, SuperGut, creates a natural alternative to GLP-1 drugs in the form of supplements, snacks and bars. His journey to become CEO of SuperGut was born out of a personal loss and a chance meeting with Dave Friedberg, the CEO of The Production Board. 

You can listen to our conversation by clicking below, downloading to your device, or heading over to Apple Podcasts, Spotify or wherever you listen to podcasts.

Primary Sidebar

Footer

  • About
  • Sponsor the Spoon
  • The Spoon Events
  • Spoon Plus

© 2016–2025 The Spoon. All rights reserved.

  • Facebook
  • Instagram
  • LinkedIn
  • RSS
  • Twitter
  • YouTube
 

Loading Comments...